Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen

Fondazione Italiana Linfomi - ETS1,927 enrolled

Overview

This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.

Study Type

OBSERVATIONAL

Enrollment

1,927

Conditions

B-Cell Lymphomas

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the current World Health Organisation Classification, from 2001 to 2007. 2. Any stage of disease. 3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant). 4. Age at least 18 years. 5. Availability of tissue biopsy at diagnosis for a possible centralized revision. 6. Availability of data on clinical involvement, laboratory, treatment and follow up. Exclusion Criteria: * None

Locations (39)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Hemocentro-Unicamp

Campinas, Brazil

Centro Medico

Santa Isabel, Brazil

Centro Paulista de Oncologia

São Paulo, Brazil

Santa Casa Medical School

São Paulo, Brazil

Clinica Ematologica Policlinico Carreggi

Florence, Firenze, Italy

Ematologia e Trapianto IRCCS, Istituto Nazionale dei Tumori

Milan, Milano, Italy

A.O.SS. Biagio, Antonio e Cesare Arrigo

Alessandria, Italy

Centro di riferimento Oncologico Oncologia Medica A

Aviano (Pordenone), Italy

USC Ematologia e Trapianto di Midollo Osseo Ospedali Riuniti di Bergamo

Bergamo, Italy

Presidio Ospedaliero A.Perrino - Divisione di Ematologia

Brindisi, Italy

...and 29 more locations